Piperacillin–tazobactam as alternative to carbapenems for ICU patients
| العنوان: | Piperacillin–tazobactam as alternative to carbapenems for ICU patients |
|---|---|
| المؤلفون: | Alexis Tabah, Christian Brun-Buisson, Vincent Jullien, Jean-Ralph Zahar, Benoit Pilmis |
| المصدر: | Annals of Intensive Care, Vol 7, Iss 1, Pp 1-17 (2017) Annals of Intensive Care |
| بيانات النشر: | Springer Science and Business Media LLC, 2017. |
| سنة النشر: | 2017 |
| مصطلحات موضوعية: | 0301 basic medicine, medicine.medical_specialty, Icu patients, Definitive Therapy, 030106 microbiology, Review, Critical Care and Intensive Care Medicine, 03 medical and health sciences, 0302 clinical medicine, Pharmacokinetics, Anesthesiology, Bloodstream infection, Ecological consequences, polycyclic compounds, Medicine, 030212 general & internal medicine, Clinical efficacy, Intensive care medicine, Outcome, business.industry, lcsh:Medical emergencies. Critical care. Intensive care. First aid, lcsh:RC86-88.9, biochemical phenomena, metabolism, and nutrition, Alternatives, Carbapenems, ESBL, Pharmacodynamics, Piperacillin/tazobactam, business, medicine.drug |
| الوصف: | Several studies suggest that alternatives to carbapenems, and particulary beta-lactam/beta-lactamase inhibitor combinations, can be used for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE)-related infections in non-ICU patients. Little is known concerning ICU patients in whom achieving the desired plasmatic pharmacokinetic/pharmacodynamic (PK/PD) target may be difficult. Also, in vitro susceptibility to beta-lactamase inhibitors might not translate into clinical efficacy. We reviewed the recent clinical studies examining the use of BL/BLI as alternatives to carbapenems for therapy of bloodstream infection, PK/PD data and discuss potential ecological benefit from avoiding the use of carbapenems. With the lack of prospective randomized studies, treating ICU patients with ESBL-PE-related infections using piperacillin–tazobactam should be done with caution. Current data suggest that BL/BLI empirical use should be avoided for therapy of ESBL-PE-related infection. Also, definitive therapy should be reserved to patients in clinical stable condition, after microbial documentation and results of susceptibility tests. Optimization of administration and higher dosage should be used in order to reach pharmacological targets. |
| تدمد: | 2110-5820 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e5f9b06cf8f7b3177c43a339669d6bfTest https://doi.org/10.1186/s13613-017-0334-xTest |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....6e5f9b06cf8f7b3177c43a339669d6bf |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 21105820 |
|---|